Tamoxifen is not effective in good prognosis patients with hepatocellular carcinoma
© Gallo et al; licensee BioMed Central Ltd. 2006
Received: 04 May 2006
Accepted: 24 July 2006
Published: 24 July 2006
Large randomised clinical trials and systematic reviews substantiate that tamoxifen is ineffective in improving survival of patients with hepatocellular carcinoma (HCC). However, a recent report suggested that the drug might prolong survival among patients with well preserved liver function. The aim of this paper is to validate this hypothesis.
We used the updated database of the phase 3 randomised CLIP-1 trial that compared tamoxifen with supportive therapy. Primary endpoint was overall survival. Treatment arms were compared within strata defined according to the Okuda stage and the CLIP-score. Survival differences were tested by the Log-rank test.
Tamoxifen was not effective in prolonging survival in Okuda I-II subgroup (p = 0.501). Median survival times were equal to 16.8 (95%CI 12.7–18.5) months for tamoxifen and 16.8 (95%CI 13.5–22.4) months for the control arms; 1-year survival probabilities were equal to 58.8% (95%CI 51.7–65.8) and 59.4 (95%CI 52.5–66.2), respectively. Similar results were observed in the better CLIP subgroup (score 0/1), without evidence of difference between the two treatment arms (p = 0.734). Median survival times were equal to 29.2 (95%CI 20.1–36.4) months with tamoxifen and 29.0 (95%CI 23.3–35.2) months without; 1-year survival probabilities were equal to 80.9% (95%CI 72.5–89.3) with tamoxifen and 77.1% (95%CI 68.6–85.7) for the control arm.
The recent suggestion that tamoxifen might be effective in the subgroup of patients with better prognosis is not supported by a reanalysis of the CLIP-1 trial. Tamoxifen should no longer be considered for the treatment of HCC patients and future trials of medical treatment should concentrate on different drugs.
At the end of '90, large randomised clinical trials showed the ineffectiveness of tamoxifen in the treatment of hepatocellular carcinoma (HCC) both in advanced [1, 2] and potentially curable patients . Since then many reviews repeatedly asserted there was no evidence of any effect of tamoxifen in improving survival of HCC patients [4–9].
Recently, the lack of a survival advantage was further confirmed by a French trial with 420 HCC patients randomly assigned tamoxifen or supportive care alone . This trial added an important piece of information because tamoxifen was found ineffective also in a HCC population with a high prevalence of alcohol-related liver cirrhosis. However, following a post-hoc unplanned subgroup analysis, the Authors suggested that tamoxifen might be effective in a population of patients without major hepatic insufficiency, i.e. those with Okuda stage I or II, and that new trials on tamoxifen are still warranted.
The methods of the CLIP-1 trial have been detailed elsewhere . Brief information is given below.
CLIP-1 multicenter randomised trial had a pragmatic approach with large and simple inclusion criteria: all patients with a life expectancy longer than three months and diagnosed less than two years before were eligible for the study. Differently from other studies, this trial was not limited to patients with advanced disease, thus we had the opportunity to assess the possible efficacy of treatment with tamoxifen even in potentially curable subjects .
Patients were centrally randomised either to tamoxifen (40 mg/day) or supportive therapy using a minimization procedure with center, evidence of disease at entry and time from HCC diagnosis as stratification variables. Overall 496 subjects entered the study from 30 Italian institutions and 477 were evaluable for the analysis, 237 assigned to the tamoxifen arm, and 240 to the control arm.
Overall survival was the only endpoint of the trial and analyses were performed according to an intention-to-treat basis. Survival curves were drawn by the Kaplan-Meier method and compared by the logrank test.
The hypothesis to be tested was that tamoxifen might be effective in patients with better prognosis, thus, according to the original study , two subgroups of the Okuda stage were derived (I/II and III/unknown). Similarly two subgroups of the CLIP score were obtained combining together the patients at better prognosis (scores 0 or 1) and at worse prognosis (scores equal to or greater than 2 or unknown).
Distributions of baseline variables by treatment arm, according to prognostic Okuda subgroups
III or unknown
Tamoxifen (n = 189)
Control (n = 196)
Tamoxifen (n = 48)
Control (n = 44)
Median (range) age, years
Evidence of disease at entry
Interval between diagnosis and entry
Percutaneous Ethanol Injection
Distributions of baseline variables by treatment arm, according to prognostic CLIP subgroups
2–6 or unknown
Tamoxifen (n = 85)
Control (n = 94)
Tamoxifen (n = 152)
Control (n = 146)
Median (range) age (years)
Evidence of disease at entry
Interval between diagnosis and entry
Percutaneous Ethanol Injection
Overall baseline variables were well balanced between the two treatment arms. As expected, more potentially curative treatments (surgery or percutaneous ethanol injection) were observed in the subgroup with the better prognosis. Less patients were classified in the better subgroup with the CLIP score than with the Okuda score.
In this paper we report a failed attempt to validate the Barbare's hypothesis  that tamoxifen might be effective in patients with better prognosis and confirm the previous evidence that there is no survival advantage for treating HCC patients with tamoxifen in addition to supportive therapy.
Because of the broad eligibility criteria applied in the CLIP-1 trial, we had already tested possible survival differences within subgroups defined by locoregional treatment . Because of the strict correlation between prognosis and locoregional treatment, the present lack of significance was expected.
We also tested the same hypothesis in subgroups defined according to the CLIP score, that currently is the most widely accepted and validated prognostic score for HCC [11, 12]. CLIP scores 0 and 1 definitely identified patients without major hepatic insufficiency better than Okuda score (Figures 1a and 2a), but once again no evidence of tamoxifen effectiveness was found.
Our results substantiate the criticism against subgroup analyses, even more urgently when they are not previously planned. In multiple subgroup analyses both more false negative results, due to the smaller size of the groups, and more false positive results, due to multiple comparisons, are expected. Exploring data in search for differences possibly depending on certain baseline characteristics may be acceptable on its own, but subgroup findings must not be over-interpreted . Although the power is usually limited, only statistical tests of interaction should be performed rather than subgroup-specific tests. Anyway, the interpretation strictly depends on whether findings are biologically plausible, how many analyses are done, whether they are planned ahead and how much strong is the statistical evidence, still being aware that most subgroup claims tend to exaggerate the truth [13, 14].
Often, it is enough to correct for multiple testing so that results are no more statistically significant and conclusions not sounded; as would have been the case in the trial recently reported by Barbare et al .
Although Barbare et al. discussed their findings must be regarded with great caution, their conclusion was that new trials are warranted in the specific population without major hepatic insufficiency. That conclusion brought about this report, but we failed to substantiate it.
Ciro Gallo has received support from AIRC (Associazione Italiana per la Ricerca sul Cancro), a non-profit charity, for studies on hepatocellular carcinoma. MDM is recipient of an AIRC fellowship. However, AIRC had no role in design, analysis and interpretation of reported data.
- Cancer of the Liver Italian Program (CLIP) Group: Tamoxifen in treatment of hepatocellular carcinoma: a randomised controlled trial. Lancet. 1998, 352: 17-20. 10.1016/S0140-6736(98)01259-8.View Article
- Chow PK, Tai BC, Tan CK, Machin D, Win KM, Johnson PJ, Also KC: High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: A multicenter randomized controlled trial. Hepatology. 2002, 36 (5): 1221-6. 10.1053/jhep.2002.36824.View ArticlePubMed
- Perrone F, Gallo C, Daniele B, Gaeta GB, Isso F, Capuano G, Adinolfi LE, Mazzanti R, Farinati F, Elba S, Piai G, Calandra M, Stanzione M, Mattera D, Aiello A, De Sio I, Castiglione F, Russo M, Persico M, Felder M, Manghisi OG, De Maio E, Di Maio M, Pignata S: Tamoxifen in the treatment of hepatocellular carcinoma: 5 year results of the CLIP-1 multicentre randomised controlled trial. Current Pharmaceutical Design. 2002, 8 (11): 1013-9. 10.2174/1381612024607063.View ArticlePubMed
- Nowak A, Findlay M, Culjak G, Stockler M: Tamoxifen for hepatocellular carcinoma (Cochrane Review). The Cochrane Library. 2006, Oxford: Update Software, 1
- Nowak A, Stockler MR, Chow PKH, Findlay M: Use of tamoxifen in advanced-stage hepatocellular carcinoma: a systematic review. Cancer. 2005, 103 (7): 1408-14. 10.1002/cncr.20963.View ArticlePubMed
- Beaugrand M, N'kontchou G, Seror O, Ganne N, Trinchet JC: Local/regional and systemic treatments of hepatocellular carcinoma. Semin Liver Dis. 2005, 25 (2): 201-11. 10.1055/s-2005-871199.View ArticlePubMed
- Llovet JM: Updated treatment approach to hepatocelluar carcinoma. J Gastroenterol. 2005, 40 (3): 225-35. 10.1007/s00535-005-1566-3.View ArticlePubMed
- Burroughs A, Hochhauser D, Meyer T: Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum. Lancet Oncol. 2004, 5 (7): 409-18. 10.1016/S1470-2045(04)01508-6.View ArticlePubMed
- Di Maio M, De Maio E, Perrone F, Pignata S, Daniele B: Hepatocellular carcinoma: systemic treatments. J Clin Gastroenterol. 2002, 35: S109-14. 10.1097/00004836-200211002-00007.View ArticlePubMed
- Barbare JC, Bouche O, Bonnetain F, Raoul JL, Rougier P, Abergel A, Boige V, Denis B, Blanchi A, Pariente A, Milan C, Bedenne L: Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma. J Clin Oncol. 2005, 23 (19): 4338-4346. 10.1200/JCO.2005.05.470.View ArticlePubMed
- Cancer of the Liver Italian Program (CLIP) Investigators: A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology. 1998, 28: 751-755. 10.1002/hep.510280322.View Article
- Cancer of the Liver Italian Program (CLIP) Investigators: Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology. 2000, 31: 840-845. 10.1053/he.2000.5628.View Article
- Assmann SF, Pocock SJ, Enos LE, Kasten LE: Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet. 2000, 355: 1064-69. 10.1016/S0140-6736(00)02039-0.View ArticlePubMed
- Brookes ST, Whitley E, Peters TJ, Mulheran PA, Egger M, Davey Smith G: Subgroup analyses in randomised controlled trials: Quantifying the risks of false-positive and false-negatives. Health Technology Assessment. 2001, 5 (33):
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/6/196/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.